---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010621"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:10:19.081715+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics reports FY2022 net loss $55.3M; cash $97.9M; ENLIGHTEN I on track for mid-2023 enrollment completion

## Summary
- Net loss for FY2022 $55.3M vs $43.5M in 2021; Q4 net loss $14.2M.
- Cash and investments $97.9M as of Dec 31, 2022; sufficient into mid-2024.
- ENLIGHTEN I Phase 3 enrollment completion on track for mid-2023; ENLIGHTEN II resume enrollment Q2 2023 (ahead of prior Q3 2023).
- BEACON Phase 2 data for LYR-220 expected Q4 2023.
- Transitioned manufacturing in-house to prepare for commercial production.

## SEC filing metadata
- accession: 0000950170-23-010621
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017023010621/0000950170-23-010621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017023010621/lyra-20230329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010621
- JSON: https://secwatch.observer/filing/0000950170-23-010621.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010621.txt

## Key facts
- Earnings Releases
  Lyra Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss for the fourth quarter and full year ended December 31, 2022 was $14.2 million and $55.3 million, respectively.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Net income: Net loss for the fourth quarter and full year ended December 31, 2022 was $14.2 million and $55.3 million, respectively
  - Result: reported results
  source text: Lyra Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017023010621/0000950170-23-010621-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.